Elebo Nnenna, Abdel-Shafy Ebtesam A, Cacciatore Stefano, Nweke Ekene Emmanuel
Department of Surgery, Faculty of Health Sciences, University of Witwatersrand, Johannesburg, Gauteng, South Africa.
Bioinformatics Unit, International Centre for Genetic Engineering and Biotechnology, Cape Town, South Africa.
Front Genet. 2023 Sep 18;14:1170571. doi: 10.3389/fgene.2023.1170571. eCollection 2023.
Pancreatic Ductal Adenocarcinoma (PDAC) is a very lethal disease that typically presents at an advanced stage and is non-compliant with most treatments. Recent technologies have helped delineate associated molecular subtypes and genetic variations yielding important insights into the pathophysiology of this disease and having implications for the identification of new therapeutic targets. Drug repurposing has been evaluated as a new paradigm in oncology to accelerate the application of approved or failed target-specific molecules for the treatment of cancer patients. This review focuses on the impact of molecular subtypes on key genomic alterations in PDAC, and the progress made thus far. Importantly, these alterations are discussed in light of the potential role of drug repurposing in PDAC.
胰腺导管腺癌（PDAC）是一种极具致死性的疾病，通常在晚期出现，且对大多数治疗方法均不敏感。近期的技术有助于明确相关的分子亚型和基因变异，从而对该疾病的病理生理学有了重要的认识，并对新治疗靶点的识别具有重要意义。药物再利用已被评估为肿瘤学中的一种新范式，以加速将已批准或失败的靶点特异性分子应用于癌症患者的治疗。本综述重点关注分子亚型对PDAC关键基因组改变的影响，以及迄今为止所取得的进展。重要的是，将根据药物再利用在PDAC中的潜在作用来讨论这些改变。
